vs
Side-by-side financial comparison of Investar Holding Corp (ISTR) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
Investar Holding Corp is the larger business by last-quarter revenue ($23.5M vs $18.6M, roughly 1.3× SCYNEXIS INC). On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 0.9%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 4.9%).
Investar Holding Corp is a U.S.-headquartered bank holding company that primarily operates across the Gulf Coast region. It delivers a full range of commercial and retail banking services, including deposit products, consumer and business loans, mortgage services, and wealth management solutions for individual clients, small and medium-sized enterprises, and commercial entities.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
ISTR vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.5M | $18.6M |
| Net Profit | — | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 30.9% | 56.3% |
| Net Margin | — | 65.7% |
| Revenue YoY | 0.9% | 1808.5% |
| Net Profit YoY | — | 376.5% |
| EPS (diluted) | $0.50 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.5M | $18.6M | ||
| Q3 25 | $24.1M | $334.0K | ||
| Q2 25 | $22.3M | $1.4M | ||
| Q1 25 | $24.0M | $257.0K | ||
| Q4 24 | $23.3M | $977.0K | ||
| Q3 24 | $22.3M | $660.0K | ||
| Q2 24 | $20.4M | $736.0K | ||
| Q1 24 | $21.4M | $1.4M |
| Q4 25 | — | $12.3M | ||
| Q3 25 | $6.2M | $-8.6M | ||
| Q2 25 | $4.5M | $-6.9M | ||
| Q1 25 | $6.3M | $-5.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $5.4M | $-2.8M | ||
| Q2 24 | $4.1M | $-14.5M | ||
| Q1 24 | $4.7M | $411.0K |
| Q4 25 | 30.9% | 56.3% | ||
| Q3 25 | 31.0% | -2516.5% | ||
| Q2 25 | 24.4% | -701.0% | ||
| Q1 25 | 32.2% | -3350.2% | ||
| Q4 24 | 31.1% | — | ||
| Q3 24 | 27.6% | -1563.6% | ||
| Q2 24 | 24.0% | -1255.0% | ||
| Q1 24 | 28.5% | -692.5% |
| Q4 25 | — | 65.7% | ||
| Q3 25 | 25.6% | -2572.2% | ||
| Q2 25 | 20.2% | -504.8% | ||
| Q1 25 | 26.3% | -2097.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | 24.1% | -425.5% | ||
| Q2 24 | 19.9% | -1964.4% | ||
| Q1 24 | 22.0% | 29.9% |
| Q4 25 | $0.50 | $0.25 | ||
| Q3 25 | $0.54 | $-0.17 | ||
| Q2 25 | $0.46 | $-0.14 | ||
| Q1 25 | $0.63 | $-0.11 | ||
| Q4 24 | $0.61 | — | ||
| Q3 24 | $0.54 | $-0.06 | ||
| Q2 24 | $0.41 | $-0.30 | ||
| Q1 24 | $0.48 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $40.0M |
| Total DebtLower is stronger | $9.8M | — |
| Stockholders' EquityBook value | $301.1M | $49.4M |
| Total Assets | $2.8B | $59.0M |
| Debt / EquityLower = less leverage | 0.03× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | $37.9M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $68.8M | ||
| Q2 24 | — | $73.0M | ||
| Q1 24 | — | $80.2M |
| Q4 25 | $9.8M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $9.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $301.1M | $49.4M | ||
| Q3 25 | $295.3M | $36.4M | ||
| Q2 25 | $255.9M | $44.5M | ||
| Q1 25 | $251.7M | $50.5M | ||
| Q4 24 | $241.3M | $55.1M | ||
| Q3 24 | $245.5M | $58.5M | ||
| Q2 24 | $230.2M | $60.4M | ||
| Q1 24 | $227.0M | $74.1M |
| Q4 25 | $2.8B | $59.0M | ||
| Q3 25 | $2.8B | $51.1M | ||
| Q2 25 | $2.7B | $60.7M | ||
| Q1 25 | $2.7B | $67.9M | ||
| Q4 24 | $2.7B | $90.6M | ||
| Q3 24 | $2.8B | $99.0M | ||
| Q2 24 | $2.8B | $107.8M | ||
| Q1 24 | $2.8B | $118.3M |
| Q4 25 | 0.03× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.2M | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | $18.4M | ||
| Q3 25 | $6.9M | $-8.7M | ||
| Q2 25 | $3.2M | $-7.5M | ||
| Q1 25 | $4.5M | $-7.5M | ||
| Q4 24 | $15.9M | $-24.0M | ||
| Q3 24 | $5.6M | $765.0K | ||
| Q2 24 | $2.8M | $-10.9M | ||
| Q1 24 | $7.8M | $-4.0M |
| Q4 25 | — | 1.50× | ||
| Q3 25 | 1.12× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 1.66× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ISTR
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
